Transdermal fentanyl for the treatment of cancer pain: A multicenter study

  • Yu Shiying
Original Articles



The multicenter clinical trial is to evaluate the effect and side effects of transdermal fentanyl for patients with cancer pain in China.


A total of 458 patients with moderate-to-severe cancer pain enrolled the multicenter study from 16 institutes. They received transdermal fentanyl for at least 15 days (between 15 and 523 days).


Baseline mean of pain intensity was 7. 92 (between 4 and 10). On day 1, 3, 6, 9, 15 and 30, the pain mean scores were decreased to 6. 05, 4.28, 3, 58, 3.06, 1.29 (P<0.001). 86.3% patients reported that the pain intensity decreased was on day 1, and the pain stabilizing control war on day 5. After the pain treatment, the patients' quality of life was significantly improved. The pain intensity (mean score 8.25) was more serious, and the effect of pain treatment was poorer in metastasis bone pain than pain in other anatomic site. The common side effects were constipation, nausea, dizzy, sedation, stomach upset, vomiting and difficulty of urination. The incidence of constipation was related with the age, while the incidence of vomiting and difficulty of urination was related with the gender.


The transdermal fentanyl patch is proving to be a safe, convenient, well tolerated and sustained effective treatment modality in the control of cancer pain.

Key words

cancer pain transdermal fentanyl pain management 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sun Y, Gu WP. Cancer pain relief guideline. 2nd, Beijing: Beijing Medical University Press, 2002.Google Scholar
  2. 2.
    Yu SY, Wang XS, Chen Y,et al. Special aspects of cancer pain management in a Chinese general hospital. Euro J Pain, 2001, 5: 15–20.CrossRefGoogle Scholar
  3. 3.
    WHO. Achieving balance in national opioids control policy: Guidelines for Assessment. Geneva, 2000.Google Scholar
  4. 4.
    Wang XS, Li TD, Yu SY,et al. China: Status of pain and palliative Care. J Pain Sympt Manage, 2002, 24: 177–179.CrossRefGoogle Scholar
  5. 5.
    Cherny N. New strategies in opioid therapy for cancer pain. J Oncol Manag, 2000, 9: 8–15.PubMedGoogle Scholar
  6. 6.
    Gourlay GK. Treatment of cancer pain with transdermal fentanyl. Lancet Oncol, 2001, 2: 165–172.PubMedCrossRefGoogle Scholar
  7. 7.
    Joranson DE, Ryan KM, Gilson AM,et al. Trends in medical use and abuse of opioid analgesics. JAMA, 2000, 283: 1710–1714.PubMedCrossRefGoogle Scholar
  8. 8.
    Mystakidou K, Befon S, Tsilika E,et al. Use of TTS fentanyl as a single opioid for cancer pain relief: a safety and efficacy clinical trial in patients naive to mild or strong opioids. Oncology, 2002, 62: 9–16.PubMedCrossRefGoogle Scholar
  9. 9.
    Bleeker CP, Bremer RC, Dongelmans DA,et al. Inefficacy of high-dose transdermal fentanyl in a patient with neuropathic pain, a case report. Eur J Pain, 2001, 5: 325–329.PubMedCrossRefGoogle Scholar
  10. 10.
    Radbruch L, Sabatowski R, Petzke F,et al. Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients. Palliat Med, 2001, 15: 309–321.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2003

Authors and Affiliations

  • Yu Shiying
    • 1
  1. 1.Cancer Center of Tongji Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Personalised recommendations